Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

医学 长春瑞滨 阿替唑单抗 内科学 临床研究阶段 肺癌 肿瘤科 化疗 胃肠病学 癌症 外科 顺铂 免疫疗法 彭布罗利珠单抗
作者
A. Vergnenègre,I. Monnet,Charles Ricordel,A. Bizieux,H. Curcio,Massimo Bernardi,R. Corre,Florian Guisier,S. Hominal,G. Le Garff,Olivier Bylicki,Chrystèle Locher,Margaux Geier,C. Chouaïd,G. Robinet
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:178: 191-197 被引量:6
标识
DOI:10.1016/j.lungcan.2023.02.020
摘要

Objective To evaluate the safety and efficacy of second-line metronomic oral vinorelbine–atezolizumab combination for stage IV non-small-cell lung cancer. Methods This was a multicenter, open-label, single-arm Phase II study performed in patients with advanced NSCLC without activating EGFR mutation or ALK rearrangement who progressed after first-line platinum-doublet chemotherapy. Combination treatment was atezolizumab (1200 mg IV day 1, every 3 weeks) and oral vinorelbine (40 mg, 3 times by week). The primary outcome was progression-free survival (PFS) during the 4-month follow-up from the first dose of treatment. Statistical analysis was based on the exact single-stage Phase II design defined by A'Hern. Based on literature data, the Phase III trial threshold was set at 36 successes in 71 patients. Results 71 patients were analyzed (median age, 64 years; male, 66.2%; ex-smokers/active smokers, 85.9%; ECOG performance status 0–1, 90.2%; non-squamous NSCLC, 83.1%; PD-L1 ≥ 50%, 4.4%). After a median follow-up of 8.1 months from treatment initiation, 4-month PFS rate was 32% (95% CI, 22–44), i.e. 23 successes out 71 patients. OS rate was 73.2% at 4 months and 24.3% at 24 months. Median PFS and OS were 2.2 (95% CI, 1.5–3.0) months and 7.9 (95% CI, 4.8–11.4) months, respectively. Overall response rate and disease control rate at 4 months were 11% (95% CI, 5–21) and 32% (95% CI, 22–44), respectively. No safety signal was evidenced. Conclusion Metronomic oral vinorelbine-atezolizumab in the second-line setting did not achieve the predefined PFS threshold. No new safety signal was reported for vinorelbine-atezolizumab combination.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小西瓜萝卜青菜完成签到,获得积分10
刚刚
思源应助虚幻采枫采纳,获得10
1秒前
1秒前
不安的可乐完成签到,获得积分10
1秒前
2秒前
nano完成签到 ,获得积分10
2秒前
da完成签到,获得积分10
2秒前
科研通AI2S应助啊啊啊啊采纳,获得10
3秒前
cyndi发布了新的文献求助20
3秒前
4秒前
852应助小小西瓜萝卜青菜采纳,获得10
6秒前
sci完成签到,获得积分10
7秒前
醉熏的鑫发布了新的文献求助10
8秒前
Nizarn发布了新的文献求助10
8秒前
9秒前
9秒前
乐呵呵完成签到,获得积分10
9秒前
9秒前
忧心的惜天完成签到 ,获得积分10
9秒前
77完成签到,获得积分10
10秒前
yz发布了新的文献求助10
10秒前
周周南完成签到 ,获得积分10
13秒前
13秒前
zz完成签到,获得积分10
13秒前
自由老头应助cyndi采纳,获得20
14秒前
努力做实验完成签到 ,获得积分10
15秒前
wf发布了新的文献求助10
15秒前
研友_ngkEgn完成签到,获得积分10
15秒前
代丽娟完成签到,获得积分10
15秒前
17秒前
快来下载文献完成签到,获得积分10
17秒前
苹果山芙完成签到,获得积分10
18秒前
煎饼狗子发布了新的文献求助10
18秒前
r41r32完成签到 ,获得积分10
19秒前
20秒前
QQ完成签到,获得积分10
21秒前
自由橘子发布了新的文献求助10
22秒前
量子星尘发布了新的文献求助50
22秒前
puppy完成签到 ,获得积分10
23秒前
orixero应助多走一步采纳,获得10
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds第二卷 1200
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038657
求助须知:如何正确求助?哪些是违规求助? 3576306
关于积分的说明 11375198
捐赠科研通 3306108
什么是DOI,文献DOI怎么找? 1819379
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066